Elevance Health stock faces 516 million US dollar CMS lawsuit
Published on 11/13/2026 at 14:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSCMS dispute puts future payments at stake
- Elevance alleges that CMS used 11 measures without the required formal rulemaking process.
- The disputed methodology affects 12 Medicare Advantage contracts and could influence their 2027 star ratings.
- No court has ruled on the merits, leaving the potential payment effect unresolved.
Elevance Health filed a complaint against the Centers for Medicare & Medicaid Services and the Department of Health and Human Services on November 6, challenging the calculation of its 2027 Medicare Advantage star ratings. The insurer alleges that CMS used 11 measures that were not adopted through the formal rulemaking process required for standards tied to Medicare payments, according to Insurance Business.
The complaint concerns 12 Elevance contracts serving members in several states and Puerto Rico, plus a national contract. Elevance says removing the disputed measures would raise each contract's rating by at least half a star. The company also argues that two medication-adherence measures used Part D prescription data outside the sources permitted for star ratings.
Why the ratings matter financially
Medicare Advantage star ratings determine access to quality bonus payments and affect the share of plan rebates that insurers retain. Elevance estimates that corrected ratings could generate 516 million US dollars in 2028 quality bonus payments and rebate retention across the affected contracts, according to the complaint. Several contracts would move across the four-star threshold if CMS recalculated the scores without the challenged measures, the filing alleges.
The case follows a May 2026 ruling involving Clover Insurance. A federal court in Georgia found parts of CMS's rating methodology unlawful and ordered a recalculation for Clover. Elevance says CMS later removed the same defective measures from Clover's 2027 ratings while retaining the measures in Elevance's published 2027 calculations. The insurer filed a separate challenge in July over its 2026 ratings, making the new case its second star-ratings action against CMS in five months.
Elevance Health stock traded at 389.75 euros on Lang & Schwarz at 14:00 CET on Friday, November 13. Without a court ruling, the possible payment benefit remains contingent on the requested recalculation and the outcome of the litigation. The allegations have not been tested on the merits.
Elevance Health at a glance
- Company: Elevance Health
- ISIN: US0367521038
- Ticker: ELV
- Lang & Schwarz quote: 389.75 euros at 14:00 CET on Friday, November 13, 2026
- Legal filing: November 6, 2026
- Disputed contracts: 12 Medicare Advantage contracts
US insurers are facing broader scrutiny over Medicare Advantage payment-linked ratings as several plans challenge the 2027 methodology in federal court; current S&P 500 market reports provide the wider market context.
Further legal filings, early court decisions and CMS action on future rating rules will determine whether the potential 2028 payment effect becomes financially relevant. More news and analyses on Elevance Health stock.
